Pluristem: Second Patient With ‘Life-Saving’ Cells Died
By David Wainer,
Business Week
| 11. 09. 2012
Pluristem Therapeutics Inc. (PSTI) said a second of the three patients given the company’s experimental stem cells has died after Pluristem touted the treatments as “life-saving.”
Pluristem shares soared after the Haifa, Israel-based company issued news releases in May, August and September announcing the treatments. Pluristem raised $34 million in a share sale in September without announcing that the first of those patients, a 7-year-old girl with a bone-marrow disease, had died. The company issued a press release today acknowledging the death of a second patient, though it wouldn’t say when the death occurred.
Pluristem sank the most in 21 months in Nasdaq Stock Market trading yesterday after Bloomberg News reported Pluristem hadn’t disclosed the girl’s death before the share sale. The company said today it wasn’t aware of her death at the time of the offering.
“The pediatric patient referred to in the Bloomberg article survived for six months, another patient survived for four months, and the third is still alive,” the company said in today’s statement. “Pluristem believes that these results exceeded longevity expectations. The unfortunate...
Related Articles
By Jason Liebowitz, The New Yorker | 03.06.2026
When Talaya Reid was in high school, in a quiet suburb of Philadelphia, she developed fatigue so severe that she spent afternoons napping instead of going out with friends. She was lethargic at school and her grades suffered, but after...
By Tania Fabo, Truthout | 02.28.2026
The reproductive tech company Orchid recently launched a genetic test that promises a whole genome sequencing report for embryos. It is the first such test commercially available to couples undergoing in vitro fertilization (IVF) and claims to detect things like...
By Émile P. Torres, Truthdig | 02.26.2026
It’s well known that Jeffrey Epstein was a super-wealthy pedophile with an extraordinary network of powerful friends: tech billionaires, politicians and academics. But few people know that he was also a transhumanist — someone who believes that we should...
By Pete Shanks
| 02.27.2026
Last month, we published “The Shameful Legacy of Tuskegee” which focused on a proposed experiment in Guinea-Bissau. The study’s plan echoed the notorious Tuskegee disaster, withholding safe, effective vaccines against hepatitis B from some newborns while inoculating others. It was to be financed by the U.S. but performed by a controversial Danish team. That project provoked a multi-national outcry, leading to a remarkable response from the World Health Organization:
WHO has significant concerns regarding the study’s scientific...
